Match!
Suanna S. Bruinooge
American Society of Clinical Oncology
48Publications
15H-index
1,129Citations
Publications 49
Newest
#1E. Garret-Mayer (American Society of Clinical Oncology)H-Index: 4
#2Melinda Kaltenbaugh (American Society of Clinical Oncology)
Last.Richard L. Schilsky (American Society of Clinical Oncology)H-Index: 66
view all 7 authors...
PURPOSECompany-reported payments from the Open Payments database (OP) have been compared with self-disclosed financial relationships made by physician authors. Discrepancies have been viewed as und...
Source
#1Kathryn F. MilehamH-Index: 3
#2Caroline Schenkel (American Society of Clinical Oncology)H-Index: 1
Last.Julie Marie Vose (UNMC: University of Nebraska Medical Center)H-Index: 84
view all 11 authors...
PURPOSE:Investigators often send reports to sponsors that incorrectly categorize adverse event (AE)s as serious or attribute AEs to investigational drugs. Such errors can contribute to high volumes...
Source
#1Suanna S. Bruinooge (American Society of Clinical Oncology)H-Index: 15
#2Shimere Sherwood (American Society of Clinical Oncology)H-Index: 1
Last.Richard L. Schilsky (American Society of Clinical Oncology)H-Index: 66
view all 4 authors...
Targeted cancer therapies are drugs and biologics designed to affect cancer cell growth by blocking or interfering with specific molecular pathways in the cancer cell. Use of targeted agents usuall...
Source
#1Tareq Al BaghdadiH-Index: 2
#2Susan Halabi (Duke University)H-Index: 60
Last.Richard L. Schilsky (American Society of Clinical Oncology)H-Index: 66
view all 14 authors...
PURPOSEThe Targeted Agent and Profiling Utilization Registry (TAPUR) Study identifies signals of antitumor activity of commercially available targeted agents in patients with advanced cancers that ...
Source
#1Ricardo H. AlvarezH-Index: 6
Last.Richard L. SchilskyH-Index: 66
view all 12 authors...
Source
Source
#1R. Donald Harvey (Emory University)H-Index: 21
#2Wendy S. Rubinstein (American Society of Clinical Oncology)H-Index: 2
Last.Suanna S. Bruinooge (American Society of Clinical Oncology)H-Index: 15
view all 17 authors...
LBA108Background: Restrictive trial eligibility criteria limit data generalizability and patient opportunity to participate. We compared numbers and characteristics of patients (pts) eligible using...
Source
#1Eugene R AhnH-Index: 2
#2Pam K. MangatH-Index: 2
Last.Richard L. SchilskyH-Index: 66
view all 20 authors...
9041Background: TAPUR is a phase II basket study evaluating anti-tumor activity of commercially available targeted agents in pts with advanced cancers with genomic alterations. Results in a cohort ...
#1Ajjai Alva (UM: University of Michigan)H-Index: 19
#2Pam K. Mangat (American Society of Clinical Oncology)H-Index: 2
Last.Richard L. Schilsky (American Society of Clinical Oncology)H-Index: 66
view all 20 authors...
1014Background: TAPUR is a phase II basket study evaluating the anti-tumor activity of commercially available targeted agents in pts with advanced cancers with specific genomic alterations. P is an...
Source
#1Heidi D. Klepin (Wake Forest Baptist Medical Center)H-Index: 24
#2Elizabeth Garrett-Mayer (MUSC: Medical University of South Carolina)H-Index: 46
Last.Dawn L. Hershman (CUMC: Columbia University Medical Center)H-Index: 58
view all 16 authors...
e18279Background: CancerLinQ Discovery (CLQD) is a real-world dataset (RWD) derived from electronic health records across the US. This analysis builds on the prior observation of cautioned use of b...
Source
12345